VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
Celotno besedilo
  • Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
    Janžič, Urška, onkologinja ...
    Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment ... receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, after the first and second doses and 3 months after a complete primary course of vaccination. Results were compared with healthy controls. Results: Of 112 patients, the seroconversion rate was 96%. A significant reduction in antibody levels was observed 3 months after vaccination in patients receiving immune checkpoint inhibitors versus control participants (p < 0.001). Adverse events were mostly mild. Conclusion: Immunogenicity after mRNA-based vaccine in cancer patients is adequate but influenced by the type of anticancer therapy. Antibody levels decline after 3 months, and thus a third vaccination is warranted.
    Vir: Future oncology. - ISSN 1479-6694 (Vol. 18, no. 23, 2022, str. 2537–2550)
    Vrsta gradiva - članek, sestavni del ; neleposlovje za odrasle
    Leto - 2022
    Jezik - angleški
    COBISS.SI-ID - 111378179
vir: Future oncology. - ISSN 1479-6694 (Vol. 18, no. 23, 2022, str. 2537–2550)
loading ...
loading ...